Evidence map›Paper›PMID 28592989›Full record

ArticleInfectious agents and cancer2017

Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria.

Olugbenga Akindele Silas, Chad J Achenbach, Lifang Hou, Robert L Murphy, Julie O Egesie, Solomon A Sagay, Oche O Agbaji, Patricia E Agaba, Jonah Musa, Agabus N Manasseh and 4 more

Erratum issuedAbstract read
In one paragraph

Article in Infectious agents and cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. HIV/AIDS Associated Lymphoma: Review.Blood and lymphatic cancer : targets and therapy · 2022
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Olugbenga Akindele SilasPathology Department, Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Chad J AchenbachFeinberg School of Medicine, Department of Medicine, Northwestern University and Center for Global Health, Chicago, Illinois USA.
Lifang HouFeinberg School of Medicine, Department of Medicine, Northwestern University and Center for Global Health, Chicago, Illinois USA.
Robert L MurphyFeinberg School of Medicine, Department of Medicine, Northwestern University and Center for Global Health, Chicago, Illinois USA.
Julie O EgesieHematology Department Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Solomon A SagayDepartment of Obstetrics and Gynecology Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Oche O AgbajiDepartment of Internal Medicine Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Patricia E AgabaDepartment of Family Medicine Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Jonah MusaDepartment of Obstetrics and Gynecology Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Agabus N ManassehPathology Department, Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Ezra D JatauHematology Department Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Ayuba M DaudaPathology Department, Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Maxwell O AkanbiDepartment of Internal Medicine Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.
Barnabas M MandongPathology Department, Faculty of Medical Sciences, University of Jos/Jos University Teaching Hospital, Jos, Plateau State Nigeria.

Funding

Northwestern/Nigeria Research Training Program in HIV and Malignancies (NN-HAM)D43TW009575 · FIC · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Chad J Achenbach, Jonah Musa · 2014 to 2026
$4.1M
FIC NIH HHS D43 TW009575
6 · The paper itself

Abstract

backgroundLymphoma is a leading cause of cancer-related death among human immunodeficiency virus (HIV)-infected individuals in the current era of potent anti-retroviral therapy (ART). Globally, mortality after HIV-associated lymphoma has profound regional variation. Little is known about HIV-associated lymphoma mortality in Nigeria and other resource-limited setting in sub-Saharan Africa. Therefore, we evaluated the all-cause mortality after lymphoma and associated risk factors including HIV at the Jos University Teaching Hospital (JUTH) Nigeria.

methodsWe conducted a ten-year retrospective cohort study of lymphoma patients managed in JUTH. The main outcome measured was all-cause mortality and HIV infection was the main exposure variable. Overall death rate was estimated using the total number of death events and cumulative follow up time from lymphoma diagnosis to death. Cox proportional hazard regression was used to assess factors associated with mortality after lymphoma diagnosis.

resultsOut of 40 lymphoma patients evaluated, 8(20.0%) were HIV positive and 32(80.0%) were HIV negative. After 127.63 person- years of follow-up, there were 16 deaths leading to a crude mortality rate of 40.0 per 100 person-years. The 2-year probability of survival was 30% for HIV-infected patients and 74% for HIV-uninfected. Median survival probability for HIV-infected patients was 2.1 years and 7.6 years for those without HIV. Unadjusted hazard of death was associated with late stage, HR 11.33(95% CI 2.55, 50.26,

conclusionOur findings suggest that HIV- infection accounted for three times probability of death in lymphoma patients compared to their HIV-uninfected counterparts due to late stage of lymphoma presentation in this population. Also initiation of chemotherapy was associated with lower probability of death among lymphoma patients managed at JUTH, Nigeria. Earlier stage at lymphoma diagnosis and prompt therapeutic intervention is likely to improve survival in these patients. Future research should undertake collaborative studies to obtain comprehensive regional data and identify unique risk factors of poor outcomes among HIV-infected patients with lymphoma in Nigeria.

Indexed as

Human immunodeficiency virusLymphomaMortalityNigeriaOutcomes

Identifiers

PMID28592989
PMCPMC5460353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.